BMS Expands Collaboration with CytomX for US$200 M Upfront
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 4 (Table of Contents)
Published: 8 Apr-2017
DOI: 10.3833/pdr.v2017.i4.2238 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Bristol-Myers Squibb (BMS) has expanded its strategic collaboration with CytomX Therapeutics to discover novel therapies that will include up to eight additional oncology and non-oncology targets using CytomX’s proprietary Probody™ antibody platform...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS